Internship

Summer 2025 – Informatics and Predictive Sciences Internship

Posted on 10/4/2024

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Summit, NJ, USA

Occupancy type may require onsite presence.

Category
Computational Biology
Genomics
Biology & Biotech
Required Skills
R
Requirements
  • Enrolled in a full-time graduate program majoring in Computational Biology or related field
  • Experience working with single-cell datasets
  • Strong experience using R/RStudio
  • Familiarity with cloud and high performance computing environments is a plus
  • Excellent communication, collaboration, and learning skills
Responsibilities
  • Survey literature to identify available and novel methods for single-cell annotation
  • Apply proposed methods to public and/or internal datasets
  • Evaluate the performance of methods tested using proposed metrics
  • Document set of scripts generated for future reference
  • Summarize and present results project teams

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and cardiovascular conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality and safety standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's AI-driven R&D enhances drug discovery and development efficiency.
  • The $3.5bn agreement with Prime Medicine boosts BMS's cell and gene-therapy pipeline.
  • BMS's commitment to ESG initiatives aligns with industry sustainability trends.

What critics are saying

  • Lawsuits against HRSA and HHS could lead to regulatory and financial challenges.
  • The $6.4 billion lawsuit by UMB poses potential financial liabilities for BMS.
  • The collaboration with AI Proteins may not yield viable therapeutic candidates.

What makes Bristol-Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE